Company Overview and News

 
Manpasand Beverages Limited - Updates

2018-09-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MANPASAND 539207

 
Manpasand Beverages Limited - Shareholders meeting

2018-09-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MANPASAND 539207

 
Manpasand Beverages Limited - Press Release

2018-08-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MANPASAND 539207

 
Manpasand Beverages sets up ₹180 crore facility in Varanasi

2018-08-24 livemint
New Delhi: Fruit juice maker Manpasand Beverages on Friday said it has completed the setting up a ₹180 crore manufacturing facility in Uttar Pradesh.
MANPASAND 539207

 
Manpasand Beverages sets up new facility in UP with Rs 180 crore investment

2018-08-24 moneycontrol
Fruit juice maker Manpasand Beverages today said it has completed the setting up a new, Rs 180 crore manufacturing facility in Uttar Pradesh (UP).
MANPASAND 539207

 
D-Street Buzz: Metals shine led by Hindustan Zinc, JSW Steel; Pfizer zooms 12%, hits fresh 52-week high

2018-08-24 moneycontrol
The Indian market continues to trade in the red this Friday afternoon with the Nifty down 24 points and trading at 11,558. The Sensex on the other hand is trading lower by 79 points and is trading at 38,257.
AMKD 500325 UBL 532715 532478 CADILAHC 532321 532483 KSCL BJJQY RLNIY EXIDEIND AXB YYBKY JSWSTEEL CNRYY AXBA EXQDY BAJFINANCE BATAINDIA CANBK 507458 500188 HINDZINC 500228 RELIANCE AMTEKAUTO HNDZY 532899 532215 GITANJALI AXISBANK RIGD 500034 YESBANK UBNC IBN UBHOLDINGS 532648 UNBWY CDLYY 539207 AXBKY GTJLY ICICIBANK 532174 520077 500086 500043 MANPASAND

 
Manpasand Beverages Limited - Updates

2018-08-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MANPASAND 539207

 
Manpasand Beverages Limited - AGM/Book Closure

2018-08-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MANPASAND 539207

 
Manpasand Beverages Limited - Record Date

2018-08-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MANPASAND 539207

 
Manpasand Beverages Limited - Shareholders meeting

2018-08-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MANPASAND 539207

 
81 firms under NSE ASM framework

2018-08-17 freepressjournal.in
New Delhi : As many as 81 firms have come under the Additional Surveillance Measure (ASM) framework of the NSE, according to the latest data available with the exchange.
ESL SHILPI AMKD MOREPENLAB EMAMIINFRA AMTEKAUTO ZENITHEXPO 531723 532513 532997 UTTAMVALUE IDBLZ 531543 512553 532775 GTLINFRA 534976 532960 JINDWORLD 533207 RADICO KSK 500254 IBVENTURES 533264 ZENTEC 533389 539207 TVSELECT VMART 532497 533218 533339 JPINFRATEC 500288 STAMPEDE 520077 MANPASAND

 
Mayday, Mayday: Auditors on high alert

2018-08-16 livemint
Mumbai: How many companies or their managements are still riding a tiger they can’t get off? That’s a question that should worry investors, and their reaction to auditor resignations in recent months shows that it does. To jog some memories, ‘riding a tiger’ is how B. Ramalinga Raju described his state when, as promoter and chairman of Satyam Computer Services Ltd, he confessed that the company’s books had been cooked for several years.
532617 JETAIRWAYS MANPASAND 539207

1
FIIs flee as Jet struggles with debt, Q1 financials

2018-08-15 livemint
Bengaluru: Foreign institutional investors (FII) sharply reduced their holding in Jet Airways Ltd during the April-June quarter, even as India’s largest full-service carrier struggled to repay debt and deferred its earnings announcement.
INDIGO IBN 532617 JETAIRWAYS TTNQY 539448 539207 ICICIBANK 532540 HDB 532174 500180 HDFCBANK TCS 534809 PCJEWELLER MANPASAND

 
BSE moves Manpasand to Group A

2018-08-14 thehindubusinessline
Manpasand Beverages on Tuesday said that the company has been upgraded to ‘Group A’ by the BSE, according to the latest revision by the exchange. Despite being placed under the Additional Surveillance Measure (ASM), the stock has been chosen for ‘Group A’. The revision in Group A will come into effect from Thursday. Along with Manpasand Beverages, 63 other companies have also been upgraded to ‘Group A’ based on BSE’s guidelines and assessment.
GRAPHITE 509488 MANPASAND 539207

 
Pressure mounts on Jet Airways to clear the air on financials after auditor trouble

2018-08-10 moneycontrol
Disagreement on reporting of a particular expense or income item with the auditor may have led to the audit committee of Jet Airways not recommending its April-June result to the board.
532617 JETAIRWAYS MANPASAND SBAZ 539207

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...